摘要
分析健康对照组４２人，甲状腺机能亢进（甲亢）初发组２６人、治疗未愈组２２人、治疗缓解组３６人的血清微球蛋白（β２－Ｍ），ＦＴ３、ＦＴ４水平。结果分别为１．１４±０．８６，６．３２±２．１０，１４．７４±４．０７；２．７２±１．９３，２９．１７±１７．２８，５０．９３±２１．１５，２．８８±２．０８，１５．２３±９．２５，２３．１９±１５．３２；１．５０±０．８６，５．２３±１．６４，１２．８３±４．８６．甲亢初发组与未愈组３项指标与对照组比较差异有高度显著性（Ｐ＜０．０１），缓解组差异无显著性（Ｐ＞０．０５）．甲亢初发组ＦＴ３、ＦＴ４与β２－Ｍ含量呈正相关，未愈组则无相关关系。４组人群甲状腺抗体阳性率分别为０％、６９％、３１％、１７％，其中初发甲亢组甲状腺微粒体抗体阳性率高（５７．７％）．在甲亢治疗早期抗体平均结合率下降速度早于β２－Ｍ、ＦＴ３、ＦＴ４，但最终恢复到正常范围又慢于它们以上３指标。
The amounts of serum β2-M、FT3 and FT4 were studied in contrast(Group A,n=42),and patients with hyperthyroidism,including primary and untreated patients (Group B, n=26),treated but uncured patients(Group C,n=22),treated and recovered patients (Group D,n=36).The results showed that there was a remarked difference in there parameters between Grop B or C and A respectively(P<0.01),but no differenace between Groups C and A.There was positive relation between FT3 or FT4 andβ2-M respectively in Group B,but not in Group C.In Group B,the positive rate of anti-thyroid antibody(TM-Ab) was 57.7% which was the highest,and second,third and the lowest in Groups B,C and A respectively.The change in the positive rate of TM-Ab was parallel to that of serumβ2-M, FT3 or FT4 in both patients and controls.
